Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT07123103

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07123103. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.

Study identification

NCT ID
NCT07123103
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Exelixis
Industry
Enrollment
150 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 18, 2025 (Actual)
Primary completion
Nov 30, 2027 (Estimated)
Completion
Feb 29, 2028 (Estimated)
Last update posted
Nov 16, 2026

2025 – 2028

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
Exelixis Clinical Site #5 Rogers Arkansas 72758 Recruiting
Exelixis Clinical Site #9 Los Angeles California 90033 Recruiting
Exelixis Clinical Site #6 Washington D.C. District of Columbia 20057 Recruiting
Exelixis Clinical Site #4 Orlando Florida 32827 Recruiting
Exelixis Clinical Site #3 Grand Rapids Michigan 49546 Recruiting
Exelixis Clinical Site #10 East Brunswick New Jersey 08816 Recruiting
Exelixis Clinical Site #7 New Brunswick New Jersey 08901 Recruiting
Exelixis Clinical Site #2 Huntersville North Carolina 28078 Recruiting
Exelixis Clinical Site #8 Houston Texas 77030 Recruiting
Exelixis Clinical Site #1 San Antonio Texas 78229 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07123103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.